Once a month, The Medical Letter provides a previously published article to JAMA to be republished.
Previous Publication: This article was published in The Medical Letter on Drugs and Therapeutics. August 1, 2016;58(1500):97-98 and updated on August 17, 2016. It is reprinted here with permission from ©The Medical Letter Inc.
For a free trial subscription to The Medical Letter, go to www.medicalletter.org/tmlj. The Medical Letter—Essential to your practice.
About The Medical Letter: The Medical Letter is a nonprofit organization that publishes biweekly new drug evaluations and treatment recommendations. The Medical Letter does not accept advertisements, gifts, grants, or donations. Financial support comes solely from sales of subscriptions, books, software, continuing education materials, and licenses.
Editors: Mark Abramowicz, MD, President; Gianna Zuccotti, MD, MPH, Vice President and Executive Editor; Jean-Marie Pflomm, PharmD, Editor in Chief
2.Whiting
PF, Wolff
RF, Deshpande
S,
et al. Cannabinoids for medical use: a systematic review and meta-analysis.
JAMA. 2015;313(24):2456-2473.
PubMedGoogle ScholarCrossref 4. Rolapitant (Varubi) for prevention and delayed chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther. 2016;58(1487):17-18.
PubMedGoogle Scholar 5.Portenoy
RK, Ganae-Motan
ED, Allende
S,
et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.
J Pain. 2012;13(5):438-449.
PubMedGoogle ScholarCrossref 6.Hill
KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review.
JAMA. 2015;313(24):2474-2483.
PubMedGoogle ScholarCrossref 7.Yadav
V, Bever
C
Jr, Bowen
J,
et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology.
Neurology. 2014;82(12):1083-1092.
PubMedGoogle ScholarCrossref 8.Devinsky
O, Marsh
E, Friedman
D,
et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Lancet Neurol. 2016;15(3):270-278.
PubMedGoogle ScholarCrossref 11.Hartman
RL, Brown
TL, Milavetz
G,
et al. Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol.
Clin Chem. 2015;61(6):850-869.
PubMedGoogle ScholarCrossref 12. Inhibitors and inducers of CYP enzymes and P-Glycoprotein.
Med Lett Drugs Ther. 2016;58(1491):e46-e47.
PubMedGoogle Scholar